# A Study of MGC026 in Participants With Advanced Solid Tumors

> **NCT06242470** · PHASE1 · RECRUITING · sponsor: **MacroGenics** · enrollment: 250 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Advanced Cancer
- Metastatic Cancer
- Squamous Cell Carcinoma of Head and Neck
- Non Small Cell Lung Cancer
- Small-cell Lung Cancer
- Bladder Cancer
- Sarcoma
- Endometrial Cancer
- Melanoma
- Castration Resistant Prostatic Cancer
- Cervical Cancer
- Colorectal Cancer
- Gastric Cancer
- Gastro-esophageal Cancer
- Pancreas Cancer
- Clear Cell Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Platinum-resistant Ovarian Cancer
- Breast Cancer
- Ovarian Cancer
- Esophageal Squamous Cell Cancer (SCC)

## Interventions

- **BIOLOGICAL:** MGC026 Dose Escalation
- **BIOLOGICAL:** MGC026 Dose for Expansion

## Key facts

- **NCT ID:** NCT06242470
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-06
- **Primary completion:** 2028-05
- **Final completion:** 2028-10
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06242470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06242470, "A Study of MGC026 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06242470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*